Articles related to Family Medicine/General Practice

The Journal of Internal Medicine stresses that, although the timing of antiviral therapy may significantly slow COVID-19 progression, the study was underpowered to evaluate the therapeutic effect of the drugs and they should continue to be used only in studies, not empirical use.

A JAMA “Original Investigation” seeks to discover the characteristics, clinical presentation, and outcomes of 5,700 patients hospitalized with COVID-19 in the United States, specifically in the New York City area.

This study in Cancer suggests the possibility, pointing to qualitative results of clinical trial principal investigators, research staff, referring clinicians, and cancer center leaders regarding their attitudes and experiences with enrolling minority patients in cancer clinical trials.

Although timely access to the results of studies evaluating patients with cancer infected with COVID-19 is urgently needed, such evidence is currently very limited. The CCC19 hopes to change all of that.

According to a recent study published in Journal of Infectious Diseases, an analysis of four different coronaviruses (OC43, 229E, HKU1 and NL63) over an 8-year period demonstrated that they were detected in a limited timeframe, from December to April and May, with a peak during January and February.

Although no proven therapies exist, this JAMA article explores potential treatments for COVID-19 in repurposed drugs (chloroquine and hydroxychloroquine), lopinavir/ritonavir and other antiretrovirals, investigational drugs such as remdesivir, adjunctive therapies, and others.